-+ 0.00%
-+ 0.00%
-+ 0.00%

Alto Neuroscience Presents ALTO-207 Development Plans for Treatment-Resistant Depression

PUBT·11/10/2026 21:37:14
Listen to the news
Alto Neuroscience Presents ALTO-207 Development Plans for Treatment-Resistant Depression
  • Alto Neuroscience expects Phase 2b topline data for ALTO-207 in treatment-resistant depression in the second half of 2027.
  • Phase 3 adjunctive treatment and monotherapy trials are planned to begin in early 2027 and the second half, respectively.
  • ALTO-300 Phase 2b depression data are expected in the first half of 2027; ALTO-100 bipolar depression data are due midyear.
  • Expected cash runway extends through 2030, with five late-stage data readouts anticipated over approximately three years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.